Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17292023 | 0.99 | LMNA (0.55) | LMNAFAAHP2RY14SMN1; SMN2KMT2A | |
| SCHEMBL15964797 | 0.88 | LMNA (0.54) | LMNAFAAHP2RY14SMN1; SMN2KMT2A | |
| SCHEMBL15964674 | 0.87 | LMNA (0.56) | LMNAFAAHP2RY14SMN1; SMN2KMT2A | |
| SCHEMBL15964796 | 0.85 | LMNA (0.51) | LMNAFAAHP2RY14KMT2ACYP1A2 | |
| SCHEMBL15964791 | 0.82 | LMNA (0.47) | LMNAFAAHKMT2ACYP1A2 | |
| SCHEMBL10080301 | 0.80 | P2RY14 (0.54) | LMNAP2RY14KMT2A | |
| SCHEMBL5560879 | 0.80 | CYP1A2 (0.46) | FAAHSMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL22412881 | 0.79 | LMNA (0.44) | LMNAFAAHKMT2ACYP1A2 | |
| SCHEMBL18939308 | 0.78 | KMT2A (0.46) | FAAHSMN1; SMN2KMT2AELANECYP1A2 | |
| SCHEMBL21569169 | 0.77 | HTR2C (0.60) | LMNAFAAHP2RY14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | LMNA 4613/4885FAAH 1491/4885P2RY14 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.